VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ICML 2021 | Strategies to achieve deep remission pre-transplant

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, explains how deep remission can be achieved in chronic lymphocytic leukemia (CLL) patients who have yet to undergo transplantation. Despite a combination of allogeneic stem cell transplantation and targeted therapies being an option for achieving remission, stem cell transplantation is not carried out in patients who are in first remission. Introduction of alternative cell therapies such as bispecific antibodies can benefit patients who are resistant to existing targeted therapies and are yet to receive stem cell transplantation. This is interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter